Chronic obstructive pulmonary disease

34 total trials 6 recruiting MedDRA PT

Filter these 34 trials by phase, country, sponsor and more.

Open in Search →

Bioequivalence study between two fluticasone propionate 250μg/salmeterol 50μg inhalation powders Ended

2023-505198-34-00 2 2023-07-31 "Healthy volunteers.Regular treatment of bronchial asthma, wh"
A Study to Evaluate the Efficacy and Safety of Astegolimab in Patients with Chronic Obstructive Pulmonary Disease Ended

2022-502234-70-00 5 2023-07-14 "Chronic Obstructive Pulmonary Disease (COPD)"
A Phase 1/2a Study Evaluating the Effects of ARO-MUC5AC Inhalation Solution in Healthy Subjects and Patients with Muco-Obstructive Lung Dise … Ended

2024-514809-67-00 9 2023-06-21 "Asthma and Chronic obstructive pulmonary disease"
Long-term Efficacy and Safety of Tozorakimab in Participants with Chronic Obstructive Pulmonary Disease with a History of Exacerbations. Ended

2022-501063-41-00 5 2023-04-20 "Chronic Obstructive Pulmonary Disease (COPD)"
Mechanistic study of the effect of itepekimab on airway inflammation in patients with COPD Ended

2024-512007-39-00 4 2022-06-20 "Chronic Obstructive Pulmonary Disease"
Study to assess efficacy, safety, and tolerability of Tozorakimab in patients with symptomatic chronic obstructive pulmonary disease (COPD) … Ended

2023-503572-24-00 5 2022-03-02 "Chronic Obstructive Pulmonary Disease (COPD)"
Study to assess efficacy, safety, and tolerability of Tozorakimab in patients with symptomatic chronic obstructive pulmonary disease (COPD) … Ended

2023-503571-19-00 5 2022-01-20 "Chronic Obstructive Pulmonary Disease (COPD)"
Study to assess the efficacy, safety, and tolerability of SAR440340/REGN3500/itepekimab in chronic obstructive pulmonary disease (COPD) (AER … Ended

2024-512012-21-00 5 2021-04-08 "Chronic Obstructive Pulmonary Disease"
Study to assess the efficacy, safety, and tolerability of SAR440340/REGN3500/itepekimab in chronic obstructive pulmonary disease (COPD) (AER … Ended

2024-512013-41-00 5 2021-03-22 "Chronic Obstructive Pulmonary Disease"
Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of Frequent Exace … Ended

2022-503050-39-00 5 2019-11-12 "Moderate to Very Severe Chronic Obstructive Pulmonary Diseas"

Showing 25–34 of 34 trials